No Data
No Data
There May Be Some Bright Spots In Shanghai Haoyuan Chemexpress' (SHSE:688131) Earnings
Shanghai Haoyuan Chemexpress Co., Ltd.'s (SHSE:688131) Largest Shareholders Are Private Companies Who Were Rewarded as Market Cap Surged CN¥855m Last Week
Shanghai Haoyuan Pharmaceutical Co., Ltd. 2024 Semi-Annual Report
Summary of the 2024 semi-annual report of Shanghai Haoyuan Pharmaceutical Co., Ltd.
Hao Yuan Pharmaceuticals (688131.SH) released its performance for the first half of the year, with a net income of 70.4077 million yuan, a year-on-year decrease of 25.77%.
Huayuan Pharmaceuticals (688131.SH) has released its semi-annual report for 2024, with revenue of 1.056 billion yuan...
Haoyuan Pharmaceuticals (688131.SH): The net income in the first half of the year was 70.4077 million yuan, a year-on-year decrease of 25.77%. It is planned to distribute a dividend of 0.4 yuan per 10 shares.
On August 28, Gelonghui announced that Haoyuan Medicine (688131.SH) released its 2024 interim report, achieving revenue of 1.056 billion yuan during the reporting period, a year-on-year increase of 19.82%; net income attributable to shareholders of the listed company was 70.4077 million yuan, a year-on-year decrease of 25.77%; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 66.4958 million yuan, a year-on-year decrease of 22.34%; basic earnings per share was 0.33 yuan. It plans to distribute a cash dividend of 0.4 yuan (tax included) per 10 shares to all shareholders.
No Data
No Data